Salim S. Virani | Lipid Lowering Therapies: Where did we start, where we are now and what the fu...
Similar Tracks
Subhasis Chatterjee | ECMO for COVID-19: Collaborative Experience from the Texas Medical Center
The Texas Heart Institute
William A. Zoghbi, MD | Aortic Regurgitation: The Changing Landscape of Diagnosis & Management
The Texas Heart Institute
Practical Insights of Cholesterol Guidelines for Secondary Prevention of ASCVD
American Heart Association
Tony Das, MD | The Future of Cardiovascular Disease Will Artificial Intelligence Replace Cardiol...
The Texas Heart Institute
Beyond LDL: Assessing and Treating Residual ASCVD Risk | Marc-Andre Cornier, MD
University of Colorado | Department of Medicine
Atrial Fibrillation in Older Adults: Watchman, Medications, & Other Treatment Options
Better Health While Aging
Yiannis S. Chatzizisis, MD, PhD | A New Digital Era in Cardiovascular Interventions
The Texas Heart Institute
3.09.23 Grand Rounds: Treatment of Lipids in 2023: Where are we now and where are we going?: Trea...
Houston Methodist DeBakey CV Education
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) What's new in 2024-2025 ?
THASL Thai Association for the Study of the Liver
Practical Strategies to Address the Impact of Increased Sodium Intake on CVD Risk
Cardiometabolic Health Congress (CMHC)